vs
C4 Therapeutics, Inc.（CCCC）与林德（LIN）财务数据对比。点击上方公司名可切换其他公司
C4 Therapeutics, Inc.的季度营收约是林德的1.3倍（$11.0M vs $8.8M），C4 Therapeutics, Inc.同比增速更快（112.8% vs 8.2%），过去两年C4 Therapeutics, Inc.的营收复合增速更高（90.4% vs -96.7%）
C4 Therapeutics是一家临床阶段生物制药企业，专注于开发靶向蛋白降解疗法，用于治疗癌症及其他存在重大未满足医疗需求的严重疾病。公司依托自有专利TORPEDO平台设计小分子降解剂清除致病蛋白，目前拥有多条肿瘤领域研发管线，并与头部制药企业达成战略合作。
林德是全球知名跨国化工企业，按市场份额及营收计为全球最大工业气体供应商。公司1879年由德国科学家、工程师卡尔·冯·林德在德国威斯巴登创立，现总部位于英国沃金，在爱尔兰注册，2018年由原林德股份公司与1907年在美国成立的普莱克斯合并组建。
CCCC vs LIN — 直观对比
营收规模更大
CCCC
是对方的1.3倍
$8.8M
营收增速更快
CCCC
高出104.5%
8.2%
两年增速更快
CCCC
近两年复合增速
-96.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $11.0M | $8.8M |
| 净利润 | $-20.5M | — |
| 毛利率 | — | 48.5% |
| 营业利润率 | -210.1% | 27.8% |
| 净利率 | -186.0% | — |
| 营收同比 | 112.8% | 8.2% |
| 净利润同比 | 40.7% | — |
| 每股收益（稀释后） | $-0.09 | $3.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCCCLIN
| Q1 26 | — | $8.8M | ||
| Q4 25 | $11.0M | $8.8B | ||
| Q3 25 | $11.2M | $8.6B | ||
| Q2 25 | $6.5M | $8.5B | ||
| Q1 25 | $7.2M | $8.1B | ||
| Q4 24 | $5.2M | $8.3B | ||
| Q3 24 | $15.4M | $8.4B | ||
| Q2 24 | $12.0M | $8.3B |
净利润CCCCLIN
| Q1 26 | — | — | ||
| Q4 25 | $-20.5M | $1.5B | ||
| Q3 25 | $-32.2M | $1.9B | ||
| Q2 25 | $-26.0M | $1.8B | ||
| Q1 25 | $-26.3M | $1.7B | ||
| Q4 24 | $-34.6M | $1.7B | ||
| Q3 24 | $-24.7M | $1.6B | ||
| Q2 24 | $-17.7M | $1.7B |
毛利率CCCCLIN
| Q1 26 | — | 48.5% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
营业利润率CCCCLIN
| Q1 26 | — | 27.8% | ||
| Q4 25 | -210.1% | 23.0% | ||
| Q3 25 | -306.4% | 27.5% | ||
| Q2 25 | -441.0% | 27.7% | ||
| Q1 25 | -402.9% | 26.9% | ||
| Q4 24 | -728.4% | 27.4% | ||
| Q3 24 | -183.9% | 25.0% | ||
| Q2 24 | -178.6% | 26.4% |
净利率CCCCLIN
| Q1 26 | — | — | ||
| Q4 25 | -186.0% | 17.5% | ||
| Q3 25 | -286.4% | 22.4% | ||
| Q2 25 | -402.6% | 20.8% | ||
| Q1 25 | -363.7% | 20.6% | ||
| Q4 24 | -667.8% | 20.8% | ||
| Q3 24 | -160.6% | 18.5% | ||
| Q2 24 | -147.6% | 20.1% |
每股收益（稀释后）CCCCLIN
| Q1 26 | — | $3.98 | ||
| Q4 25 | $-0.09 | $3.28 | ||
| Q3 25 | $-0.44 | $4.09 | ||
| Q2 25 | $-0.37 | $3.73 | ||
| Q1 25 | $-0.37 | $3.51 | ||
| Q4 24 | $-0.50 | $3.61 | ||
| Q3 24 | $-0.35 | $3.22 | ||
| Q2 24 | $-0.26 | $3.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.6M | $4.0M |
| 总债务越低越好 | — | $24.7M |
| 股东权益账面价值 | $256.6M | $40.1M |
| 总资产 | $359.1M | $86.3M |
| 负债/权益比越低杠杆越低 | — | 0.62× |
8季度趋势，按日历期对齐
现金及短期投资CCCCLIN
| Q1 26 | — | $4.0M | ||
| Q4 25 | $74.6M | $5.1B | ||
| Q3 25 | $58.8M | $4.5B | ||
| Q2 25 | $78.2M | $4.8B | ||
| Q1 25 | $51.3M | $5.3B | ||
| Q4 24 | $55.5M | $4.8B | ||
| Q3 24 | $59.6M | $5.2B | ||
| Q2 24 | $73.1M | $4.6B |
总债务CCCCLIN
| Q1 26 | — | $24.7M | ||
| Q4 25 | — | $20.7B | ||
| Q3 25 | — | $18.6B | ||
| Q2 25 | — | $19.7B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | — | $15.3B | ||
| Q3 24 | — | $17.5B | ||
| Q2 24 | — | $16.9B |
股东权益CCCCLIN
| Q1 26 | — | $40.1M | ||
| Q4 25 | $256.6M | $38.2B | ||
| Q3 25 | $154.4M | $38.6B | ||
| Q2 25 | $174.1M | $38.5B | ||
| Q1 25 | $195.1M | $38.0B | ||
| Q4 24 | $216.0M | $38.1B | ||
| Q3 24 | $242.7M | $39.2B | ||
| Q2 24 | $247.1M | $38.2B |
总资产CCCCLIN
| Q1 26 | — | $86.3M | ||
| Q4 25 | $359.1M | $86.8B | ||
| Q3 25 | $265.5M | $86.0B | ||
| Q2 25 | $296.5M | $86.1B | ||
| Q1 25 | $319.5M | $82.7B | ||
| Q4 24 | $349.6M | $80.1B | ||
| Q3 24 | $376.1M | $82.5B | ||
| Q2 24 | $381.1M | $80.2B |
负债/权益比CCCCLIN
| Q1 26 | — | 0.62× | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.1M | — |
| 自由现金流经营现金流 - 资本支出 | — | $898.0K |
| 自由现金流率自由现金流/营收 | — | 10.2% |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $4.2B |
8季度趋势，按日历期对齐
经营现金流CCCCLIN
| Q1 26 | — | — | ||
| Q4 25 | $-22.1M | $3.0B | ||
| Q3 25 | $-31.2M | $2.9B | ||
| Q2 25 | $-12.1M | $2.2B | ||
| Q1 25 | $-33.3M | $2.2B | ||
| Q4 24 | $-17.9M | $2.8B | ||
| Q3 24 | $-24.1M | $2.7B | ||
| Q2 24 | $-5.0M | $1.9B |
自由现金流CCCCLIN
| Q1 26 | — | $898.0K | ||
| Q4 25 | — | $1.6B | ||
| Q3 25 | $-31.6M | $1.7B | ||
| Q2 25 | — | $954.0M | ||
| Q1 25 | — | $891.0M | ||
| Q4 24 | $-17.9M | $1.6B | ||
| Q3 24 | $-24.1M | $1.7B | ||
| Q2 24 | $-5.2M | $796.0M |
自由现金流率CCCCLIN
| Q1 26 | — | 10.2% | ||
| Q4 25 | — | 17.9% | ||
| Q3 25 | -281.5% | 19.4% | ||
| Q2 25 | — | 11.2% | ||
| Q1 25 | — | 11.0% | ||
| Q4 24 | -346.5% | 18.8% | ||
| Q3 24 | -157.2% | 19.9% | ||
| Q2 24 | -43.1% | 9.6% |
资本支出强度CCCCLIN
| Q1 26 | — | — | ||
| Q4 25 | — | 16.6% | ||
| Q3 25 | 3.7% | 14.8% | ||
| Q2 25 | — | 14.8% | ||
| Q1 25 | — | 15.7% | ||
| Q4 24 | 0.1% | 15.1% | ||
| Q3 24 | 0.1% | 12.8% | ||
| Q2 24 | 1.6% | 13.7% |
现金转化率CCCCLIN
| Q1 26 | — | — | ||
| Q4 25 | — | 1.98× | ||
| Q3 25 | — | 1.53× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.76× | ||
| Q2 24 | — | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
